RxDoctor Payments Data

Michael McClaid, MD

Family Medicine · Bremen, INNPI 1003831207

Payments from drug & device makers

$4,157in general payments, 2019–2025

Across 249 payments — averaging $16.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$570
  • AstraZeneca$542
  • Novo Nordisk$348
  • Pfizer$312
  • Lilly USA, LLC$245
  • Bayer$226
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$4,137100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,157 in reported general payments places this provider in the 80th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$29,052
Medicare patients
116
Services billed
368

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide57$60,747
EliquisApixaban74$60,550
TrulicityDulaglutide24$29,564
JardianceEmpagliflozin21$21,321
LinzessLinaclotide13$18,943
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$18,286
MounjaroTirzepatide15$16,279
XareltoRivaroxaban12$15,065
Tresiba Flextouch U-100Insulin Degludec18$8,764
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$8,693
Breo ElliptaFluticasone/Vilanterol12$4,884
Vilazodone Hcl18$2,903
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen79$1,996
Omeprazole120$1,777
Gabapentin91$1,503

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$348$60,74757 claims
PfizerEliquis$312$60,55074 claims
Lilly USA, LLCTrulicity, Mounjaro, Olanzapine$245$46,45270 claims
GSKTrelegy Ellipta, Breo Ellipta$44$23,17038 claims
Boehringer IngelheimJardiance$127$21,32121 claims
AbbVieLinzess$570$18,94313 claims
Johnson & JohnsonXarelto$107$15,06512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Bremen

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →